PTEN, EGFR, ATRX, TP53 and IDH mutations were all oncogenic drivers, predominantly related to molecular diagnosis and different prognosis in glioma (Louis et al., 2016; Diplas et al., 2018). This evidence concerns the gene IDH2 and central nervous system cancer.